Prot# SA-309JG: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients with Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Project: Research project

Project Details

StatusFinished
Effective start/end date1/16/15 → 1/16/18

Funding

  • Parexel (SA-309JG)
  • Chugai Pharmaceutical Co., Ltd. (SA-309JG)